Search

Your search keyword '"Le Blanc, K."' showing total 353 results
Start Over Author "Le Blanc, K."
353 results on '"Le Blanc, K."'

20. Improved survival after allogeneic haematopoietic stem cell transplantation in recent years: P646

Author

Ringden, O., Ackefors, M., Berglund, S., Blennow, O., Dahllof, G., Dlugosz, A., Garming-Legert, K., Gertow, J., Gustafsson, B., Hassan, M., Hassan, Z., Hauzenberger, D., Hagglund, H., Karlsson, H., Klingspor, L., Kumlien, G., Le Blanc, K., Ljungman, P., Machaczka, M., Marschall, H.-U., Mattsson, J., Olsson, R., Omazic, B., Sairafi, D., Schaffer, M., Svahn, B.-M., Svenberg, P., Swartling, L., Szakos, A., Uhlin, M., Uzunel, M., Watz, E., Wernerson, A., Wikman, A., Wikstrom, A.-C., Winiarski, J., and Remberger, M.

Published
2011

39. Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells

Author

Thielen, F.W. (Frederick), Blommestein, H.M. (Hedwig), Oosten, L.E.M. (Liesbeth), Calkoen, F.G.J., Lankester, A.C. (Arjan), Zwaginga, J.J. (Jaap), Le Blanc, K. (Katarina), Redondo, A. (Alba), Sánchez‐Guijo, F. (Fermin), Algeri, M. (Mattia), Locatelli, F. (Franco), Fibbe, W.E. (Willem), Uyl-de Groot, C.A. (Carin), Thielen, F.W. (Frederick), Blommestein, H.M. (Hedwig), Oosten, L.E.M. (Liesbeth), Calkoen, F.G.J., Lankester, A.C. (Arjan), Zwaginga, J.J. (Jaap), Le Blanc, K. (Katarina), Redondo, A. (Alba), Sánchez‐Guijo, F. (Fermin), Algeri, M. (Mattia), Locatelli, F. (Franco), Fibbe, W.E. (Willem), and Uyl-de Groot, C.A. (Carin)

Abstract

__Objective:__ No standard second‐line treatment exists for acute graft‐versus‐host disease steroid‐refractory (SR‐aGvHD), and long‐term outcomes remain poor. Mesenchymal stromal cells (MSCs) have been evaluated as treatment, but no disease model (DM) exists that integrates and extrapolates currently available evidence. The aim of this study was to develop such a DM to describe the natural history of SR‐aGvHD and to predict long‐term outcomes. __Method:__ The DM was developed in collaboration with experts in haematology‐oncology. Subsequently, a model simulation was run. Input parameters for transition and survival estimates were informed by published data of clinical trials on MSC treatment for SR‐aGvHD. Parametric distributions were used to estimate long‐term survival rates after MSCs. __Results:__ The newly developed DM is a cohort model that consists of eight health states. For the model simulation, we obtained data on 327 patients from 14 published phase II trials. Due to limited evidence, DM structure was simplified and several assumptions had to be made. Median overall survival was 3.2 years for complete response and 0.5 years for no complete response. __Conclusion:__ The DM provides a comprehensive overview on the second‐line treatment pathway for aGvHD and enables long‐term predictions that can be used to perform a cost‐effectiveness analysis comparing any treatment for SR‐aGvHD.

Published
2018
Full Text
View/download PDF

40. Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model

Author

Thielen, F. W., Blommestein, H. M., Oosten, L. E. M., Calkoen, F. G., Lankester, A. C., Zwaginga, J. J., Le Blanc, K., Redondo, A., Sanchez-Guijo, F., Algeri, M., Locatelli, Franco, Fibbe, W. E., Uyl-de Groot, C. A., Locatelli F. (ORCID:0000-0002-7976-3654), Thielen, F. W., Blommestein, H. M., Oosten, L. E. M., Calkoen, F. G., Lankester, A. C., Zwaginga, J. J., Le Blanc, K., Redondo, A., Sanchez-Guijo, F., Algeri, M., Locatelli, Franco, Fibbe, W. E., Uyl-de Groot, C. A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Objective: No standard second-line treatment exists for acute graft-versus-host disease steroid-refractory (SR-aGvHD), and long-term outcomes remain poor. Mesenchymal stromal cells (MSCs) have been evaluated as treatment, but no disease model (DM) exists that integrates and extrapolates currently available evidence. The aim of this study was to develop such a DM to describe the natural history of SR-aGvHD and to predict long-term outcomes. Method: The DM was developed in collaboration with experts in haematology-oncology. Subsequently, a model simulation was run. Input parameters for transition and survival estimates were informed by published data of clinical trials on MSC treatment for SR-aGvHD. Parametric distributions were used to estimate long-term survival rates after MSCs. Results: The newly developed DM is a cohort model that consists of eight health states. For the model simulation, we obtained data on 327 patients from 14 published phase II trials. Due to limited evidence, DM structure was simplified and several assumptions had to be made. Median overall survival was 3.2 years for complete response and 0.5 years for no complete response. Conclusion: The DM provides a comprehensive overview on the second-line treatment pathway for aGvHD and enables long-term predictions that can be used to perform a cost-effectiveness analysis comparing any treatment for SR-aGvHD.

Published
2018

41. Second?line treatment for acute graft?versus?host disease with mesenchymal stromal cells: A decision model.

Author

Thielen, Frederick, Blommestein, Hedwig, Oosten, LEM, Calkoen, FG, Lankester, AC, Zwaginga, JJ, Le Blanc, K, Redondo, A, Sánchez?Guijo, F, Algeri, M, Locatelli, F (Franco), Fibbe, WE, Uyl - de Groot, Carin, Thielen, Frederick, Blommestein, Hedwig, Oosten, LEM, Calkoen, FG, Lankester, AC, Zwaginga, JJ, Le Blanc, K, Redondo, A, Sánchez?Guijo, F, Algeri, M, Locatelli, F (Franco), Fibbe, WE, and Uyl - de Groot, Carin

Abstract

Objective No standard second?line treatment exists for acute graft?versus?host disease steroid?refractory (SR?aGvHD), and long?term outcomes remain poor. Mesenchymal stromal cells (MSCs) have been evaluated as treatment, but no disease model (DM) exists that integrates and extrapolates currently available evidence. The aim of this study was to develop such a DM to describe the natural history of SR?aGvHD and to predict long?term outcomes. Method The DM was developed in collaboration with experts in haematology?oncology. Subsequently, a model simulation was run. Input parameters for transition and survival estimates were informed by published data of clinical trials on MSC treatment for SR?aGvHD. Parametric distributions were used to estimate long?term survival rates after MSCs. Results The newly developed DM is a cohort model that consists of eight health states. For the model simulation, we obtained data on 327 patients from 14 published phase II trials. Due to limited evidence, DM structure was simplified and several assumptions had to be made. Median overall survival was 3.2 years for complete response and 0.5 years for no complete response. Conclusion The DM provides a comprehensive overview on the second?line treatment pathway for aGvHD and enables long?term predictions that can be used to perform a cost?effectiveness analysis comparing any treatment for SR?aGvHD.

Published
2018

45. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.

Author

Simonson, OE, Mougiakakos, D, Heldring, N, Bassi, G, Johansson, HJ, Dalén, M, Jitschin, R, Rodin, S, Corbascio, M, El Andaloussi, S, Wiklander, OPB, Nordin, JZ, Skog, J, Romain, C, Koestler, T, Hellgren-Johansson, L, Schiller, P, Joachimsson, P-O, Hägglund, H, Mattsson, M, Lehtiö, J, Faridani, OR, Sandberg, R, Korsgren, O, Krampera, M, Weiss, DJ, Grinnemo, K-H, Le Blanc, K, Simonson, OE, Mougiakakos, D, Heldring, N, Bassi, G, Johansson, HJ, Dalén, M, Jitschin, R, Rodin, S, Corbascio, M, El Andaloussi, S, Wiklander, OPB, Nordin, JZ, Skog, J, Romain, C, Koestler, T, Hellgren-Johansson, L, Schiller, P, Joachimsson, P-O, Hägglund, H, Mattsson, M, Lehtiö, J, Faridani, OR, Sandberg, R, Korsgren, O, Krampera, M, Weiss, DJ, Grinnemo, K-H, and Le Blanc, K

Published
2016

46. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

Author

Freedman MS, Bar Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A, MSC Study Group, MARTINO , GIANVITO, Freedman, M, Bar Or, A, Atkins, Hl, Karussis, D, Frassoni, F, Lazarus, H, Scolding, N, Slavin, S, Le Blanc, K, Uccelli, A, MSC Study, Group, and Martino, Gianvito

Subjects
Central Nervous System, medicine.medical_specialty, Neurology, Multiple Sclerosis, International Cooperation, Inflammation, Animals, Central Nervous System, physiopathology, Cooperative Behavior, Double-Blind Method, Evidence-Based Medicine, Humans, International Cooperation, Mesenchymal Stem Cell Transplantation, Multiple Sclerosis, physiopathology/surgery, Nerve Regeneration, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Research Design, Bioinformatics, Mesenchymal Stem Cell Transplantation, Double-Blind Method, medicine, Animals, Humans, Remyelination, Cooperative Behavior, Randomized Controlled Trials as Topic, Evidence-Based Medicine, business.industry, Multiple sclerosis, Regeneration (biology), Mesenchymal stem cell, medicine.disease, Nerve Regeneration, Transplantation, medicine.anatomical_structure, Research Design, Immunology, Practice Guidelines as Topic, physiopathology/surgery, Neurology (clinical), medicine.symptom, Stem cell, physiopathology, business
Abstract

Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. Since it is likely that the first such studies will probably involve only small numbers of patients in a few centers, we formed an international panel comprising multiple sclerosis neurology and stem cell experts, as well as immunologists. The aims were to derive a consensus on the utilization of mesenchymal stem cells for the treatment of multiple sclerosis, along with protocols for the culture of the cells and the treatment of patients. This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients.

Published
2010

49. Mesenchymal stem cells for acute graft-versus-host disease/Authors' reply

Author

Miura, Yuji, Kami, Masahiro, Tsubokura, Masaharu, Takei, Naoko, Komatsu, Tsunehiko, Le Blanc, K, Fibbe, W, Frassoni, F, Locatelli, Franco, Ringdén, O, Locatelli, F (ORCID:0000-0002-7976-3654), Miura, Yuji, Kami, Masahiro, Tsubokura, Masaharu, Takei, Naoko, Komatsu, Tsunehiko, Le Blanc, K, Fibbe, W, Frassoni, F, Locatelli, Franco, Ringdén, O, and Locatelli, F (ORCID:0000-0002-7976-3654)

Abstract

Besides the immune regulatory role of mesenchymal stem cells, in models of experimental injury, intravenous administration of these cells improves organ healing, mainly through paracrine effects and a shift from the production of proinflammatory to anti-inflammatory cytokines at the site of injury.2,3 Furthermore, we have previously shown that immune reconstitution improves after mesenchymal stem-cell infusion, with resolution of graft-versus-host disease and subsequent tapering of immunosuppressive drugs.4 However, we acknowledge that the present study is insufficiently powered to exclude an effect of mesenchymal stem cells on the rate of infections.

Published
2008

50. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells

Author

Le Blanc, K., Samuelsson, H., Gustafsson, B., Remberger, M., Sundberg, B., Arvidson, Johan, Ljungman, P., Lönnies, H., Nava, S., Ringdén, O., Le Blanc, K., Samuelsson, H., Gustafsson, B., Remberger, M., Sundberg, B., Arvidson, Johan, Ljungman, P., Lönnies, H., Nava, S., and Ringdén, O.

Abstract

Seven patients underwent treatment with mesenchymal stem cells (MSCs), together with allogeneic hematopoietic stem cell transplantation (HSCT). MSCs were given to three patients for graft failure and four patients were included in a pilot study. HSCT donors were three human leukocyte antigen (HLA)-identical siblings, three unrelated donors and one cord blood unit. The conditioning was myeloablative in four patients and reduced in three patients. MSC donors were HLA-identical siblings in three cases and haploidentical in four cases. Neutrophil counts >0.5 ×109/l was reached at a median of 12 (range 10-28) days. Platelet counts >30 x 109/l was achieved at a median of 12 (8-36) days. Acute graft-versus-host disease (GVHD) grade 0-l was seen in five patients. Two patients developed grade II, which in one patient evolved into chronic GVHD. One severe combined immunodeficiency (SCID) patient died of aspergillosis, the others are alive and well. One patient, diagnosed with aplastic anemia had graft failure after her first transplantation and severe Henoch-Schönlein Purpura (HSP). After retransplantation of MSCs and HSCs, she recovered from both the HSP and aplasia. Thus, co-transplantation of MSC resulted in fast engraftment of absolute neutrophil count (ANC) and platelets and 100% donor chimerism, even in three patients regrafted for graft failure/rejection.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results